AUS
NZ
UK
CA
USA
IND
Highlights
- Conavi Medical Corp. has completed a business combination, resulting in a reverse takeover.
- The focus will be on advancing the Novasight Hybrid™ System for coronary procedures.
- A concurrent private placement raised significant proceeds to support ongoing operations.
Conavi Medical Corp., formerly Titan Medical Inc.(TSX:TMD) , has completed a notable business combination with Conavi Medical Inc. This transaction, structured as a reverse takeover, establishes Conavi Medical Corp. as the resulting issuer. The newly combined company will concentrate on further commercializing and developing its proprietary Novasight Hybrid™ System. This system is designed to assist in guiding minimally invasive coronary procedures, a key area of focus in the medical device sector.
The Novasight Hybrid™ System
The Novasight Hybrid™ System is designed to aid in common minimally invasive coronary procedures. The system combines imaging technology with procedural guidance, potentially enhancing the precision and safety of these procedures. The focus on coronary care aligns with the broader trend within the medical device sector, where companies are developing more sophisticated tools for treating cardiovascular conditions.
Concurrent Private Placement
Alongside the completion of the business combination, Conavi Medical conducted a concurrent private placement. This financing effort saw the issuance of subscription receipts, which were later converted into common shares and warrants of the resulting issuer. The total proceeds from this offering have been earmarked for Conavi's ongoing operations, including the commercialization of its medical systems. These funds, placed in escrow during the transaction, have now been released to the company to support its growth and development.
Escrow Release and Future Development
The proceeds raised through the private placement were held in escrow until the completion of the transaction. After deducting certain fees and expenses, the funds have been made available to Conavi. This financial backing is intended to propel the continued development and commercialization of the company's medical technologies, particularly the Novasight Hybrid™ System.
